logo

Eagle Pharmaceuticals Inc (EGRX)



Trade EGRX now with
  Date
  Headline
11/8/2017 6:52:15 AM Eagle Pharmaceuticals Q3 EPS $0.98 Vs $0.73 Last Year
10/17/2017 7:34:53 AM Eagle Pharmaceuticals Announces New Patent For RYANODEX
9/20/2017 6:55:09 AM Eagle Licenses Japanese Rights For Bendamustine Hydrochloride Rapid Infusion Injection Products To SymBio
8/9/2017 6:51:40 AM Eagle Pharma Q2 Revenue Grows 22% Year-over-year To $50.1 Mln
7/27/2017 12:32:35 PM William Blair Is Lowering Eagle Pharmaceuticals Inc (EGRX) FY18 Estimate To 3.23 From 3.83
7/27/2017 12:32:20 PM William Blair Is Lowering Eagle Pharmaceuticals Inc (EGRX) FY17 Estimate To 3.29 From 3.80
7/27/2017 12:31:59 PM William Blair Is Cutting Eagle Pharmaceuticals Inc (EGRX) FY18 Rev. Estimate To 235.2 M From 284.1 M
7/27/2017 12:31:38 PM William Blair Is Cutting Eagle Pharmaceuticals Inc (EGRX) FY17 Rev. Estimate To 245.9 M From 268.0 M
7/27/2017 10:19:39 AM RBC Capital Markets Is Lowering Eagle Pharmaceuticals Inc (EGRX) 2019 Rev. Estimate To 388.6 M From 414.6 M
7/27/2017 10:19:28 AM RBC Capital Markets Is Lowering Eagle Pharmaceuticals Inc (EGRX) 2018 Rev. Estimate To 201.1 M From 252.3 M
7/27/2017 10:19:17 AM RBC Capital Markets Is Cutting Eagle Pharmaceuticals Inc (EGRX) 2017 Rev. Estimate To 232.2 M From 252.2 M
7/27/2017 10:19:05 AM RBC Capital Markets Is Cutting Eagle Pharmaceuticals Inc (EGRX) Q3 17 Rev. Estimate To 49.4 M From 59.4 M
7/27/2017 10:18:38 AM RBC Capital Markets Is Cutting Eagle Pharmaceuticals Inc (EGRX) 2019 Estimate To 8.16 From 9.09
7/27/2017 10:18:28 AM RBC Capital Markets Is Lowering Eagle Pharmaceuticals Inc (EGRX) 2018 Estimate To 2.52 From 4.36
7/27/2017 10:18:17 AM RBC Capital Markets Is Cutting Eagle Pharmaceuticals Inc (EGRX) 2017 Estimate To 3.59 From 4.32
7/27/2017 10:18:07 AM RBC Capital Markets Is Lowering Eagle Pharmaceuticals Inc (EGRX) Q3 17 Estimate To 0.71 From 1.07